Introduction Advanced Hormone Receptor-Positive Breast Cancer

Slides:

Advertisements

Similar presentations

SABCS 2011 BOLERO-2 Updated Results

Advertisements

Neoadjuvant Hormone Treatment of Breast Cancer H.S.A. Oldenburg E.J.Th. Rutgers J.M. Dixon symposium 29 juni 2005.

Department of Surgery, United Christian Hospital Aromatase Inhibitors Current Use in Breast Cancer JHGR 16 Jan 2005 Dr. Sharon Chan Department of Surgery,

Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.

1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.

A Comparison of Fulvestrant 500 mg with Anastrozole as First-line Treatment for Advanced Breast Cancer: Follow-up Analysis from the FIRST Study Robertson.

Heterogeneity in hormone receptor positive breast cancer

ESMO 2011 Breast Cancer BOLERO-2 Authors: CARE Faculty (Drs. Anil Joy and Sunil Verma) Date posted: October 12, 2011.

S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.

Targeting endocrine-resistance pathways in breast cancer

Cyclin Kinases inhibitors and beyond

¿Qué ver en ASCO 2017?.

CCO Independent Conference Coverage

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

New Insights in the Hormone Therapy for Breast Cancer

PALOMA-2: Addition of Palbociclib to Frontline Letrozole Significantly Improves PFS in Postmenopausal ER+/HER2- Advanced Breast Cancer CCO Independent.

PHEREXA: Survival Data

Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.

Endocrine Therapy for Metastatic Breast Cancer

Optimizing Combination Endocrine Therapy in HR-Positive Advanced Breast Cancer.

Presented By Luca Malorni at 2017 ASCO Annual Meeting

S1207: Phase III randomized, placebo-controlled trial adding 1 year of everolimus to adjuvant endocrine therapy for patients with high-risk, HR+, HER2-

SAFETY AND EFFICACY OF EVEROLIMUS PLUS EXEMESTANE IN METASTATIC BREAST CANCER BEYOND THE SECOND LINE TREATMENT: A SINGLE INSTITUTION EXPERIENCE M. Giampaglia,

Endocrine Combinations in HR-Positive MBC: The Future Is Now

Evolving Paradigms in the Management of HR-Positive Breast Cancer

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.

Volume 14, Issue 10, Pages (September 2013)

The Nurse View: Hormone Receptor-Positive Advanced Breast Cancer

Expanding Horizons in the Clinical Care of ER-Positive, HER2-Negative Metastatic Breast Cancer.

HR positive, Her-2 negative MBC

New Horizons in the Management of Advanced Breast Cancer

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update

Overall Program Goals. Overall Program Goals Current Approaches.

Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.

Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.

Navigating New Treatment Landscapes in HR-Positive, HER2-Negative Metastatic Breast Cancer.

The Nurse View: Overcoming Challenges Associated With Cancer Immunotherapy.

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

CDK4/6 Inhibitors in Breast Cancer:

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

Bergh J et al. SABCS 2009;Abstract 23.

CDK4/6 Inhibitors in Practice

Optimizing Management of Advanced Bladder Cancer

Managing gBRCA-Positive Metastatic Breast Cancer

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

Using CDK4/6 Inhibitors to Manage HR-Positive Metastatic Breast Cancer

Treatment of HR+ Breast Cancer: A Clinical Update

Hormone Receptor-Positive Advanced Breast Cancer:

Vincenzo Adamo Luminal Metastatic Breast Cancer:

Baselga J et al. SABCS 2009;Abstract 45.

Breast Cancer Statistics

CDK4/6 Biomarkers: Issues and Opportunities

The Road to Quality Improvement in HER2-Positive Breast Cancer

Hormone Receptor-Positive Advanced Breast Cancer Introduction

ABSTRACT ABCSG 6a MA17-1 MA.17R NSABP B-33. Extended Adjuvant Therapy With Aromatase Inhibitor Among Postmenopausal Breast Cancer.

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

New Paradigms in HR-Positive Advanced Breast Cancer

Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion.

CDK 4/6 Inhibitors in Breast Cancer

Martin M et al. Proc SABCS 2012;Abstract S1-7.

Challenges in LA SCCHN.

CDK4/6 Biomarkers: Issues and Opportunities

Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.

Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer

CDK4/6 Inhibitors.

Real-World Evidence.

DISSECTING THE DECISION

Evaluating the Totality of Evidence

Miquel Àngel Seguí Palmer ¿Ciclinas para todas?

Presentation transcript:

Adding Evidence to Frontline Hormone Receptor-Positive Breast Cancer Treatments

Introduction Advanced Hormone Receptor-Positive Breast Cancer

First-Line Endocrine Therapy in Advanced Breast Cancer Choice of ET ± CDK 4/6 Inhibitor

Visceral Crisis

FALCON Anastrozole vs Fulvestrant in Hormone Receptor-Positive Advanced Breast Cancer

FALCON Trial Results

Fulvestrant in ER-Positive Advanced Breast Cancer CONFIRM Phase 3, Double-Blind Trial

Comparison of Recent First-Line Studies for ER-Positive Advanced Breast Cancer

Overcoming Endocrine Resistance in Metastatic Breast Cancer

PALOMA-2 Palbociclib + Letrozole vs Letrozole Alone

MONALEESA-2 Ribociclib + Letrozole vs Letrozole in Hormone Receptor-Positive Advanced Breast Cancer

Palbociclib Management of Hematological Toxicities

How Do We Determine First-Line Therapy?

BOLERO-2 Everolimus + Exemestane vs Placebo + Exemestane

SWISH Trial Dexamethasone-Based Mouthwash for Stomatitis

Concluding Remarks

Abbreviations

Abbreviations (cont)